10-Q: Chromocell Therapeutics Reports Q3 2024 Results, Cites Ongoing Development of Pain Therapeutics

Chromocell Therapeutics reported a net loss of $6.0 million for the nine months ended September 30, 2024, while continuing to advance its pain treatment programs.

Summary

• Chromocell Therapeutics Corporation reported a net loss of $1.69 million for the three months ended September 30, 2024, and a net loss of $6.03 million for the nine months ended September 30, 2024.
• The company's operating expenses totaled $2.05 million for the quarter and $5.75 million for the nine-month period.
• General and administrative expenses increased to $1.16 million for the quarter and $3.16 million for the nine months, primarily due to increased compensation, marketing, D&O insurance, capital market, board related, and stock-based compensation expenses.
• Research and development expenses rose to $414,639 for the quarter and $894,200 for the nine months, driven by increased chemistry manufacturing and controls (CMC) costs.
• Professional fees decreased to $472,604 for the quarter but increased to $1.69 million for the nine months, with fluctuations in legal and consulting fees.
• The company completed its initial public offering (IPO) in February 2024, raising approximately $5.7 million in net proceeds.
• As of September 30, 2024, the company had cash of approximately $1.3 million and a working capital deficit of $1.4 million.
• The company is developing three pain treatment programs: Neuropathic Pain (CC8464), Eye Pain (CT2000), and a Depot Program (CT3000).
• The company expects to start human trials for the depot injection formulation of CT3000 in early 2026.
• The company has licensed spray formulations from Benuvia Operations LLC, including a Diclofenac spray, a Rizatriptan spray, and an Ondansetron spray.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its clinical programs and secured funding through an IPO, the significant net losses, working capital deficit, and going concern warning raise concerns. The company's reliance on future capital raises and the identified material weaknesses in internal controls further contribute to a negative sentiment.

Positives

• The company successfully completed its IPO, raising $5.7 million in net proceeds.
• The company is actively developing three distinct pain treatment programs.
• The company has secured a licensing agreement for additional pain treatment formulations.
• The company obtained a default judgment against its former CEO and Chromocell Holdings, resulting in a gain of $363,091.
• The company has commenced development of a topical ophthalmic formulation of CT2000 and expects trials to start in 2025.

Negatives

• The company reported a significant net loss of $6.03 million for the nine months ended September 30, 2024.
• The company has a working capital deficit of $1.4 million as of September 30, 2024.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is reliant on third-party software for its financial systems and cannot ensure there are no vulnerabilities in these systems.
• The company lacks the necessary corporate accounting resources to maintain adequate segregation of duties.

Risks

• The company's ability to continue as a going concern is uncertain, with substantial doubt raised by management.
• The company may need to raise additional funds through strategic partnerships or the capital markets, with no assurance of success.
• The company's operations are sensitive to general business and economic conditions, including global conflicts.
• The company faces risks related to the biotechnology regulatory environment, technological advances, and competition.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is involved in legal proceedings, including a claim from Parexel International.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in connection with its ongoing research and development activities. The company believes that the net proceeds from the IPO, together with its existing cash, will be sufficient to fund its operations and capital expenses through the end of 2024. The company may also raise additional funding through strategic relationships, public or private equity or debt financings, credit facilities, grants or other arrangements.

Management Comments

• Management believes there is substantial doubt about its ability to continue to operate as a going concern and fund its operations through at least the next twelve months following the issuance of these financial statements.
• Management believes that the net proceeds from the IPO, together with our existing cash, will be sufficient to fund our operations and capital expenses through the end of 2024.

Industry Context

The company is operating in the competitive biotech industry, focusing on novel pain therapeutics. The company's focus on NaV1.7 blockers and non-opioid pain treatments aligns with the industry's push for alternatives to traditional pain management methods. The company's programs target specific pain conditions, including neuropathic pain, eye pain, and post-operative pain, which are areas of unmet medical need.

Comparison to Industry Standards

• The company's financial results, particularly the net losses and cash burn, are typical for early-stage biotech companies focused on drug development.
• The company's reliance on external funding through capital markets and strategic partnerships is also common in the biotech industry.
• The company's focus on specific pain indications, such as Erythromelalgia (EM) and idiopathic small fiber neuropathy (iSFN), is a strategy often employed by smaller biotech companies to target niche markets.
• The company's development of multiple programs (CC8464, CT2000, CT3000) is a common approach to diversify risk and increase the likelihood of success.
• The company's licensing agreement with Benuvia for spray formulations is a strategic move to expand its pipeline and address additional pain-related conditions.
• Compared to larger pharmaceutical companies, Chromocell is operating with significantly less capital and resources, which is reflected in its financial statements and operational scale.
• The company's approach to clinical trials, including the slow dose escalation study for CC8464, is consistent with industry best practices for managing potential side effects and optimizing drug efficacy.
• The company's pursuit of orphan drug designations for EM and iSFN is a common strategy to secure market exclusivity and tax advantages.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a demand letter from an attorney representing Chromocell Holdings and the company's former CEO, Mr. Christian Kopfli, alleging improper termination and seeking monetary damages.
• The company commenced a lawsuit against Mr. Kopfli and Chromocell Holdings, asserting breach of contract and fiduciary duty.
• The company was awarded a default judgment against Mr. Kopfli and Chromocell Holdings.
• The company received a demand letter from an attorney representing Parexel International (IRL) Limited, seeking payment of allegedly unpaid principal and interest on a note between Chromocell Holdings and Parexel.
• The company denies liability for the amounts sought by Parexel.

Related Party Transactions

• The company entered into a Consultant Agreement with Camden Capital LLC, a company controlled by Mr. Knuettel, the company's CEO and CFO.
• The company entered into a promissory note with Camden Capital LLC for approximately $131,868.
• The company had a $40,400 receivable due from Chromocell Holdings as of September 30, 2024.
• The company issued 2,600 shares of Series C Convertible Redeemable Preferred Stock to Chromocell Holdings.
• The company entered into bridge notes with related party investors including Chromocell Holdings, Boswell Prayer Ltd., Motif Pharmaceuticals Ltd, Aperture Healthcare Ventures Ltd., MDB Merchants Park LLC, Balmoral Financial Group LLC and AME Equities LLC.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional funds through the issuance of securities.
• Employees may be affected by the company's financial instability and potential need to curtail operations.
• Customers and suppliers may be impacted by the company's ability to continue as a going concern.
• Creditors may be at risk due to the company's financial challenges and potential need to restructure debt.
• The company's ability to develop and commercialize new pain therapeutics could have a positive impact on patients suffering from chronic pain.

Next Steps

• The company plans to continue investing in the development of CC8464, CT2000, and CT3000.
• The company expects to start human trials for the depot injection formulation of CT3000 in early 2026.
• The company plans to develop clinical programs for the spray formulations licensed from Benuvia.
• The company intends to move into animal toxicity studies for CT2000 eye drops in the second half of 2024.
• The company plans to conduct a Phase 2a POC study in 2025 to assess the potential efficacy of CC8464 in EM and iSFN patients.
• The company expects the slow dose escalation study for CC8464 to take approximately nine months in total.
• The company is working on the development of the Phase 2a POC plan and expects to launch the Phase 2a POC study in 2025.
• The company expects to complete the Reincorporation Merger in the fourth quarter of 2024.

Key Dates

Keywords

biotech, pharmaceutical, pain management, neuropathic pain, eye pain, post-operative pain, NaV1.7, clinical trials, drug development, IPO, CC8464, CT2000, CT3000, Benuvia, Diclofenac, Rizatriptan, Ondansetron